ABSTRACT
Introduction Fungal infection represents an increasingly important clinical entity for first-world clinicians. Despite the enormous impact of highly active antiretroviral therapy on opportunistic fungal infection, mucocutaneous infection with Candida spp. or life-threatening conditions subsequent to Cryptococcus or Pneumocystis jiroveci var. carinii continues apace.
